Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
作者信息
Ulas Ezgi B, Bahce Idris
机构信息
Department of Pulmonary Medicine, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
出版信息
Transl Lung Cancer Res. 2023 Jul 31;12(7):1369-1371. doi: 10.21037/tlcr-23-329. Epub 2023 Jul 18.
Abstract
摘要
相似文献
1
Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?可切除非小细胞肺癌的新辅助免疫化疗：周期越多越好吗？
Transl Lung Cancer Res. 2023 Jul 31;12(7):1369-1371. doi: 10.21037/tlcr-23-329. Epub 2023 Jul 18.
2
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers.局部晚期非小细胞肺癌的术前免疫化疗：临床结局、最佳周期数及外周免疫标志物分析
Transl Lung Cancer Res. 2022 Dec;11(12):2364-2381. doi: 10.21037/tlcr-22-439.
3
Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer.基于放射组学的Nomogram 模型预测潜在可切除的非小细胞肺癌患者新辅助免疫化疗主要病理缓解的开发和验证。
Front Immunol. 2023 Feb 16;14:1115291. doi: 10.3389/fimmu.2023.1115291. eCollection 2023.
4
Comprehensive F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study.基于 F-FDG PET 的全面放射组学在提升可切除 III 期非小细胞肺癌新辅助免疫化疗病理反应中的作用：一项初步研究。
Front Immunol. 2022 Nov 17;13:994917. doi: 10.3389/fimmu.2022.994917. eCollection 2022.
5
Short-term outcomes of robot-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a single-center retrospective study.新辅助免疫化疗的非小细胞肺癌患者行机器人辅助与电视辅助胸腔镜手术的短期疗效比较：单中心回顾性研究。
Front Immunol. 2023 Jul 11;14:1228451. doi: 10.3389/fimmu.2023.1228451. eCollection 2023.
6
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.新辅助 PD-1 抑制剂（信迪利单抗）联合化疗（白蛋白紫杉醇联合卡铂）治疗可切除 IIIA/IIIB 期非小细胞肺癌的疗效和安全性的初步分析：一项单臂、Ⅱ期临床试验。
J Cancer Res Clin Oncol. 2023 Feb;149(2):819-831. doi: 10.1007/s00432-021-03896-w. Epub 2022 Feb 22.
7
Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression.病例报告：一例 NSCLC 新辅助免疫化疗假性进展中从冷肿瘤向热肿瘤的转化。
Front Immunol. 2021 Feb 17;12:633534. doi: 10.3389/fimmu.2021.633534. eCollection 2021.
8
Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases.可切除的IIIA期鳞状非小细胞肺癌患者的新辅助卡瑞利珠单抗与化疗：三例临床经验
Front Oncol. 2022 Sep 13;12:843116. doi: 10.3389/fonc.2022.843116. eCollection 2022.
9
Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.可切除的鳞状非小细胞肺癌对新辅助PD-1抑制剂和化疗的病理反应及安全性
Front Oncol. 2022 Oct 14;12:956755. doi: 10.3389/fonc.2022.956755. eCollection 2022.
10
Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.可切除非小细胞肺癌新辅助治疗中免疫治疗的现状和未来展望。
Asia Pac J Clin Oncol. 2022 Aug;18(4):335-343. doi: 10.1111/ajco.13665. Epub 2021 Nov 23.
引用本文的文献
1
[Analysis of Efficacy and Safety of Neoadjuvant Immunochemotherapy in Patients
with Stage IB-IIIB Non-small Cell Lung Cancer].[IB-IIIB期非小细胞肺癌患者新辅助免疫化疗的疗效与安全性分析]
Zhongguo Fei Ai Za Zhi. 2025 Jun 20;28(6):415-426. doi: 10.3779/j.issn.1009-3419.2025.106.16.
2
Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review.接受新辅助治疗的非小细胞肺癌患者循环肿瘤DNA的价值、进展与挑战：一项叙述性综述
J Thorac Dis. 2024 Jul 30;16(7):4742-4755. doi: 10.21037/jtd-24-265. Epub 2024 Jul 4.
本文引用的文献
1
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers.局部晚期非小细胞肺癌的术前免疫化疗：临床结局、最佳周期数及外周免疫标志物分析
Transl Lung Cancer Res. 2022 Dec;11(12):2364-2381. doi: 10.21037/tlcr-22-439.
2
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.新辅助纳武利尤单抗联合化疗治疗可切除肺癌。
N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11.
3
Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.新辅助免疫检查点抑制剂在可切除非小细胞肺癌中的应用：一项系统评价。
ESMO Open. 2021 Oct;6(5):100244. doi: 10.1016/j.esmoop.2021.100244. Epub 2021 Aug 31.
4
Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.在一项真实世界肺癌研究中，基质肿瘤浸润淋巴细胞对免疫治疗疗效的惊人影响。
Lung Cancer. 2021 Mar;153:81-89. doi: 10.1016/j.lungcan.2021.01.013. Epub 2021 Jan 14.
Zotero 插件